No Data
No Data
No Data
No Data
No Data
Lucid Diagnostics: Strong Buy Rating With Significant Market Potential Despite Near-Term Losses
TipRanksApr 15 17:15
Needham: Reiterates Lucid Diagnostics (LUCD.US) rating and adjusted from buy to buy rating, target price is $2.50.
Needham: Reiterates Lucid Diagnostics (LUCD.US) rating and adjusted from buy to buy rating, target price is $2.50.
Zhitong FinanceApr 12 16:40
Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path
TipRanksApr 12 04:45
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
TipRanksApr 11 01:50
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...
PR NewswireApr 8 20:30
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
TipRanksMar 29 19:46
No Data
No Data